Clinical Trial Update: Safety and Effectiveness of Sustained Release Bupropion in Treating Individuals With Schizophrenia Who Smoke [Phase 4]

View source ↗

Summary

Phase 4 trial update examining the safety and effectiveness of sustained-release bupropion in people with schizophrenia who smoke; the study has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Schizophrenia
• Tobacco Use Disorder

Drugs mentioned

• WELLBUTRIN SR (BUPROPION HYDROCHLORIDE)

Snippet

Sponsor: National Institute on Drug Abuse (NIDA) | Conditions: Tobacco-Use Disorder, Schizophrenia | Phase 4 | Status: COMPLETED